44-amino-acid synthetic GHRH analogue with trans-3-hexenoic acid modification for enhanced proteolytic resistance. Studied for selective visceral adipose tissue (VAT) reduction and pulsatile endogenous GH release patterns in metabolic research models.
Tesamorelin is a synthetic 44-amino-acid analogue of human GHRH (growth hormone-releasing hormone). The N-terminal addition of a trans-3-hexenoic acid moiety dramatically resists dipeptidyl peptidase IV (DPP-IV) degradation, extending plasma half-life from minutes (native GHRH) to ~26 minutes. This stabilisation preserves pulsatile GH release patterns rather than producing tonic elevation.
The N-terminal trans-3-hexenoic acid modification blocks DPP-IV cleavage of the first two amino acids. This is the same enzyme that limits native GHRH to a 2–7 minute half-life — Tesamorelin's modification extends activity ~10-fold.
GHRHR is Gs-coupled. Receptor activation drives adenylyl cyclase, raising intracellular cAMP. cAMP-dependent protein kinase A phosphorylates transcription factors driving GH gene expression alongside acute GH pulse release.
Released GH binds hepatic GH receptors, triggering IGF-1 synthesis. Elevated IGF-1 mediates many of the anabolic, lipolytic, and tissue-remodelling effects observed in metabolic research models.
Tesamorelin holds FDA approval for HIV-associated lipodystrophy under the trade name Egrifta. Published Phase III trials demonstrated 15–18% VAT reduction over 26 weeks of daily administration in this specific population. The data have informed broader research into pulsatile-GHRH approaches to visceral adiposity.
Refs: Falutz J et al., N Engl J Med (2007); Stanley TL et al., JAMA (2014)
Aged-rodent research has explored Tesamorelin's effects on age-related GH decline, with measurable improvements in executive-function tasks and reduced hepatic steatosis. The mechanism is hypothesised to involve restored IGF-1 tone in tissues with age-impaired GH-axis signalling.
Refs: Baker LD et al., Arch Neurol (2012)
Each batch is independently tested by a third-party ISO-accredited laboratory. The analysis below reflects Batch AV-2025-TES-016, tested 22 January 2025.
| Test Parameter | Method | Specification | Result | Status |
|---|---|---|---|---|
| Identity | ESI-MS / MS-MS | Matches theoretical m/z | Confirmed (5135 Da) | PASS |
| Purity (HPLC) | RP-HPLC C18, 210nm | ≥98.0% | 99.3% | PASS |
| Water content | Karl Fischer | ≤8.0% | 5.5% | PASS |
| Heavy metals | ICP-MS | ≤10 ppm | <2 ppm | PASS |
| Endotoxins | LAL chromogenic | ≤10 EU/mg | <1 EU/mg | PASS |
| Form | Temperature | Duration |
|---|---|---|
| Lyophilised powder | −20°C (strongly preferred) | 24 months |
| Reconstituted | 2–8°C | ≤14 days (sensitive) |
Wipe vial with 70% IPA.
For 2 mg vial, add 2 mL BAC water → 1 mg/mL stock. Inject very slowly along the inner vial wall.
Swirl extremely gently. Vortex/shaking can fragment the long chain.
Refrigerate. Use promptly to avoid degradation of the methionine residue and N-terminal modification.
VAT has higher GH-receptor density and greater lipolytic sensitivity than subcutaneous adipose tissue. Pulsatile GH release (as triggered by Tesamorelin) preferentially activates hormone-sensitive lipase in visceral depots, with measurable subcutaneous changes being smaller in clinical studies. The depot-selective effect is consistent across rodent and human research.
Both are GHRH analogues with modifications for protease resistance. Tesamorelin (GHRH 1-44, hexenoic-acid modified) has a ~26 minute half-life. CJC-1295 No DAC (GHRH 1-29, tetrasubstituted) has ~30 minute half-life. CJC-1295 with DAC has extended half-life via albumin binding. The full 1-44 sequence of Tesamorelin distinguishes it; the additional 15 amino acids may contribute to specific tissue distribution.
Endogenous GH release peaks during early slow-wave sleep. Administering Tesamorelin before sleep aligns the pharmacologically-stimulated GH pulse with the natural pulse window, maximising amplitude and avoiding daytime somatostatin tone that would blunt the response.
Yes. Sustained Tesamorelin administration produces measurable IGF-1 elevation, typically reaching the upper-normal range. IGF-1 mediates many of the downstream anabolic and lipolytic effects. Research protocols often monitor IGF-1 as a downstream pharmacodynamic biomarker of GH-axis activation.
Independently verified by third-party ISO-accredited laboratory. COA available on request.
View Tesamorelin in Store → Reconstitution Protocol Guide